Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP806949.RAfRfu_ICfTHho-R-TmkYix7ZIJ2lw5koBz6VhaV4pXdk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP806949.RAfRfu_ICfTHho-R-TmkYix7ZIJ2lw5koBz6VhaV4pXdk130_assertion type Assertion NP806949.RAfRfu_ICfTHho-R-TmkYix7ZIJ2lw5koBz6VhaV4pXdk130_head.
- NP806949.RAfRfu_ICfTHho-R-TmkYix7ZIJ2lw5koBz6VhaV4pXdk130_assertion description "[Previously, we suggested that imatinib incorporation into conventional chemotherapy as an alternative (imatinib interim therapy) might be a useful strategy for bridging the time to allogeneic stem cell transplantation (SCT) for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP806949.RAfRfu_ICfTHho-R-TmkYix7ZIJ2lw5koBz6VhaV4pXdk130_provenance.
- NP806949.RAfRfu_ICfTHho-R-TmkYix7ZIJ2lw5koBz6VhaV4pXdk130_assertion evidence source_evidence_literature NP806949.RAfRfu_ICfTHho-R-TmkYix7ZIJ2lw5koBz6VhaV4pXdk130_provenance.
- NP806949.RAfRfu_ICfTHho-R-TmkYix7ZIJ2lw5koBz6VhaV4pXdk130_assertion SIO_000772 15657178 NP806949.RAfRfu_ICfTHho-R-TmkYix7ZIJ2lw5koBz6VhaV4pXdk130_provenance.
- NP806949.RAfRfu_ICfTHho-R-TmkYix7ZIJ2lw5koBz6VhaV4pXdk130_assertion wasDerivedFrom befree-20140225 NP806949.RAfRfu_ICfTHho-R-TmkYix7ZIJ2lw5koBz6VhaV4pXdk130_provenance.
- NP806949.RAfRfu_ICfTHho-R-TmkYix7ZIJ2lw5koBz6VhaV4pXdk130_assertion wasGeneratedBy ECO_0000203 NP806949.RAfRfu_ICfTHho-R-TmkYix7ZIJ2lw5koBz6VhaV4pXdk130_provenance.